Answer
Nilotinib binds with high affinity to BCR-ABL's ATP-binding site, potently inhibiting its ABL tyrosine kinase activity, including wild-type and 32/33 imatinib-resistant mutant forms, thereby selectively inhibiting proliferation and inducing apoptosis in cell lines and primary Philadelphia chromosome-positive leukaemia cells from CML patients.
Sources for this answer
- Tasigna 50mg, 150mg and 200 mg hard capsulesNovartis Pharmaceuticals UK Ltd · emc · SmPC §5.1 Pharmacodynamic properties · Version 39Document updated
Sources checked